Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag248 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Alec W Freyn und 12 weiteren Autor:innen. Beteiligte Einrichtung: Moderna, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Immunity, Cellular, SARS-CoV-2. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Moderna, Inc.
Abstract (Originalsprache)
Background
Cell-mediated immunity contributes to durable protection against COVID-19. mRNA-1283 vaccine, encoding the receptor-binding and N-terminal domains of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein, elicits higher neutralizing antibody responses than mRNA-1273, which encodes the full-length spike protein. We report T-cell responses following mRNA-1283 vaccination in preclinical and clinical studies.
Methods
For the preclinical evaluation, BALB/c mice received a 2-dose primary series of mRNA-1273 (days 1 and 22), followed by 1 dose of mRNA-1283.222 or mRNA-1273.222 (ancestral + BA.4/BA.5; day 63). C57BL/6 mice received mRNA-1283.815 or mRNA-1273.815 (XBB.1.5; days 1 and 22). T-cell analyses were conducted on spleens from all vaccinated BALB/c and C57BL mice (collected on days 77 and 36, respectively). In the clinical setting, a group of adult (≥18 years) participants in a randomized phase 2 trial (NCT05137236) received 1 dose of mRNA-1283 (ancestral SARS-CoV-2), mRNA-1283.211 (ancestral + beta), mRNA-1283.529 (BA.1), or mRNA-1273 (ancestral), and their SARS-CoV-2 S-protein–specific T-cell responses at days 1 (baseline), 29, 181, and 366 postvaccination were measured.
Results
In the mice studies, mRNA-1283 elicited potent S1-directed CD4+ and CD8+ T-cell responses. In the phase 2 study, mRNA-1283 increased S1-specific CD4+ and CD8+ Th1 responses at day 29 postvaccination compared with baseline; responses persisted through day 366 and were similar to mRNA-1273 for all tested strains (ancestral, beta, and BA.1).
Conclusions
In preclinical and clinical studies, mRNA-1283 induced T-cell responses similar to mRNA-1273.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Moderna, Inc., Cambridge, Massachusetts, USA.
ORCID-Profile: Cathal Harmon, Shannon McGrath, Spyros Chalkias
Förderung
- Moderna, Inc
Zitieren
APA
Freyn, A. W., Budigi, Y., Girard, B., Santos, G., Harmon, C., Hasan, M. M., McGrath, S., Paila, Y. D., Carfi, A., Edwards, D., Wahid, R., Das, R., & Chalkias, S. (2026). Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag248
Vancouver
Freyn AW, Budigi Y, Girard B, Santos G, Harmon C, Hasan MM, et al. Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag248
BibTeX
@article{Freyn2026,
author = {Freyn, Alec W and Budigi, Yadunanda and Girard, Bethany and Santos, Genesis and Harmon, Cathal and Hasan, Md Mahmudul and McGrath, Shannon and Paila, Yamuna D and Carfi, Andrea and Edwards, Darin and Wahid, Rahnuma and Das, Rituparna and Chalkias, Spyros},
title = {Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag248}
}
EUVIMED